News

News Feed

Meat And Colorectal Cancer Risk: Scientists Suggest Potential Mechanisms
Wed, 10 Mar 2010 09:00:00 PST
Scientists in the US who undertook a large study to investigate what biological mechanisms might be behind the already established link between colorectal cancer and consumption of red and processed meat, confirmed that such a link exists and suggested the main players are three compounds: heme iron, nitrate/nitrite, and heterocyclic amines...

2010 Recipient Of Minority Scholar Award Will Conduct Clinical Research On Leukemia
Wed, 10 Mar 2010 08:00:00 PST
Alison Walker, MD, has been selected to receive the ASH-AMFDP Award, and will begin her research in acute myeloid leukemia in July of this year...

Research Identifies New Mechanism Regulating Embryonic Development
Wed, 10 Mar 2010 05:00:00 PST
A Princeton University-led research team has discovered that protein competition over an important enzyme provides a mechanism to integrate different signals that direct early embryonic development. The work suggests that these signals are combined long before they interact with the organism's DNA, as was previously believed, and also may inform new therapeutic strategies to fight cancer...

Genetic Variant Greatly Increases Lung Cancer Risk For Light Smokers
Wed, 10 Mar 2010 04:00:00 PST
Individuals with a certain type of genetic susceptibility to lung cancer face a greatly increased risk for the deadly disease with even a small exposure to cigarette smoke, a study team that includes researchers from the University of Cincinnati (UC) has concluded...

Cellectar Completes Enrollment In Phase I Clinical Trial Of Lead Drug Candidate (131)I-CLR1404 For The Treatment Of Solid Malignancies
Wed, 10 Mar 2010 02:00:00 PST
Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year...

University Of Florida Researchers Find Cancer-fighting Properties In Papaya Tea
Wed, 10 Mar 2010 02:00:00 PST
The humble papaya is gaining credibility in Western medicine for anticancer powers that folk cultures have recognized for generations. University of Florida researcher Nam Dang, M.D., Ph.D., and colleagues in Japan have documented papaya's dramatic anticancer effect against a broad range of lab-grown tumors, including cancers of the cervix, breast, liver, lung and pancreas...

Professor Discovers Link Between Low Oxygen Levels In Body And Cancer-Aiding Protein; Could Help Treatments For Retinoblastoma, Breast Cancer
Wed, 10 Mar 2010 01:00:00 PST
What began as research into how diabetics could possibly preserve their eyesight has led to findings that could prolong the vision of children afflicted with retinoblastoma...

Dependence Receptors : A New Weapon To Inhibit Tumors?
Wed, 10 Mar 2010 01:00:00 PST
The interaction of a ligand (Neurotrophine-3) and its dependence receptor (TrkC) constitutes a novel mechanism for tumor control in pediatric cancers such as neuroblastoma, and may also be important to the inhibition of other cancers such as breast cancer...

Perceived Health Can Predict Survival Of Esophago-gastric Cancer
Wed, 10 Mar 2010 01:00:00 PST
Changes in patients' self-rated quality of life after treatment for esophago-gastric cancer can predict the chances for long-term survival. This is the result researchers at the Swedish medical university Karolinska Institutet made, in a new study published in the Journal of Clinical Oncology. The patient's self-rated quality of life, provide indications of whether he or she will survive...

Designer Nano Luggage To Carry Drugs To Diseased Cells
Wed, 10 Mar 2010 01:00:00 PST
For the first time, scientists have succeeded in growing empty particles derived from a plant virus and have made them carry useful chemicals. The external surface of these nano containers could be decorated with molecules that guide them to where they are needed in the body, before the chemical load is discharged to exert its effect on diseased cells...

mtm Laboratories Announces The European Launch Of CINtec(R) PLUS
Wed, 10 Mar 2010 00:00:00 PST
mtm laboratories, a privately held diagnostics company announced the launch of CINtec® PLUS, the company's next generation cervical cancer screening product with unmatched accuracy for the screening and management for cervical cancer...

Rexahn Pharmaceuticals Issued Japanese Patent For Anti-cancer Compound Archexin(R)
Tue, 09 Mar 2010 23:00:00 PST
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®...

Argos Therapeutics Presents Positive Phase 2 Data Of Its Arcelis? Personalized Immunotherapy Platform In Metastatic RCC At ASCO GU Symposium
Tue, 09 Mar 2010 22:00:00 PST
Argos Therapeutics announced the presentation of positive data from a Phase 2 trial that evaluated the safety, clinical response and immune response of AGS-003 treatment in newly diagnosed patients with metastatic renal cell carcinoma (mRCC). The data were discussed March 7 in a poster presentation at the ASCO Genitourinary Cancers Symposium...

Millennium Announces First Clinical Data For TAK-700 Prostate Molecule At ASCO GU
Tue, 09 Mar 2010 17:00:00 PST
Millennium: The Takeda Oncology Company today announced the presentation of safety, pharmacokinetic and efficacy data from the Phase I portion of a Phase I/II clinical trial evaluating TAK-700 in patients with metastatic castration resistant prostate cancer (mCRPC)...

ImmunoGen, Inc. Announces Orphan Drug Designation Granted To IMGN901 For Treatment Of Merkel Cell Carcinoma By US FDA And EU COMP
Tue, 09 Mar 2010 16:00:00 PST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC)...

New Method To Grow Arteries Could Lead To 'Biological Bypass' For Heart Disease
Tue, 09 Mar 2010 05:00:00 PST
A new method of growing arteries could lead to a "biological bypass" - or a non-invasive way to treat coronary artery disease, Yale School of Medicine researchers report with their colleagues in the April issue of Journal of Clinical Investigation. Coronary arteries can become blocked with plaque, leading to a decrease in the supply of blood and oxygen to the heart...

The Potential For Using Algae To Produce Human Therapeutic Proteins
Tue, 09 Mar 2010 05:00:00 PST
Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algae - rapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels...

New Research Shows Immune Cells Use Bungee Of Death To Kill Dangerous Cells
Tue, 09 Mar 2010 04:00:00 PST
Immune cells ensnare dangerous cells that are on the run with a bungee-like nanotube, according to research published in the Proceedings of the National Academy of Sciences. The study, by researchers from Imperial College London, shows that natural killer (NK) cells use this bungee to destroy cells that could otherwise escape them...

ESMO Conference On Sarcoma And GIST: Spotlight On Rare Tumors In Hunt For New Cancer Treatments
Tue, 09 Mar 2010 04:00:00 PST
New breakthrough treatments for the most common cancers could soon come from cutting-edge research into some of the world's rarest tumors...

News From The Journal Of Clinical Investigation: March 8, 2010
Tue, 09 Mar 2010 03:00:00 PST
Warning sign for potential anticancer approach One treatment being investigated as an adjuvant for anticancer immunotherapies is the use of molecules that trigger the proteins TLR7 and TLR8. For example, the TLR7 stimulant imiquimod is used for the treatment of skin cancer and metastatic melanoma...

Like Little Golden Assassins, 'Smart' Nanoparticles Identify, Target And Kill Cancer Cells
Tue, 09 Mar 2010 02:00:00 PST
Another weapon in the arsenal against cancer: Nanoparticles that identify, target and kill specific cancer cells while leaving healthy cells alone. Led by Carl Batt, the Liberty Hyde Bailey Professor of Food Science, the researchers synthesized nanoparticles shaped something like a dumbbell made of gold sandwiched between two pieces of iron oxide...

Improvements Needed In Genomic Test Result Discussions
Tue, 09 Mar 2010 01:00:00 PST
One in three early stage breast cancer patients who received genomic testing when deciding about treatment options felt they did not fully understand their discussions with physicians about their test results and their risk of the disease recurring, a new study has found...

Varian Medical Systems Names Dr. John Adler As Chief Of New Clinical Applications
Tue, 09 Mar 2010 00:00:00 PST
Varian Medical Systems (NYSE: VAR) announced that it has appointed John R. Adler, Jr., M.D., as Vice President and Chief of New Clinical Applications for the company. Dr. Adler, a renowned neurosurgeon, professor of Neurosurgery and Radiation Oncology at Stanford University, and past CEO, chairman and founder of Accuray, Inc...

Life Technologies, TGen And US Oncology Partner On Groundbreaking Breast Cancer Sequencing Research
Mon, 08 Mar 2010 05:00:00 PST
Life Technologies Corporation (NASDAQ:LIFE) announced that it is collaborating with the Translational Genomics Research Institute (TGen) and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies...

Occupational Sunlight Exposure And Kidney Cancer Risk In Men
Mon, 08 Mar 2010 04:00:00 PST
According to a new study, men employed in occupations with potential exposure to high levels of sunlight have a reduced risk of kidney cancer compared with men who were less likely to be exposed to sunlight at work. The study did not find an association between occupational sunlight exposure and kidney cancer risk in women...